MannKind Corporation MNKD
Updated: 16 Jun 2026
No signal published yet
We already track MannKind and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow MannKind Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow MannKind free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 29, 2026, the FDA approved the label expansion of Afrezza (inhaled insulin) for use in children and adolescents aged 6 and older with diabetes. This approval was supported by results from the company's INHALE-1 clinical trial. The company also recently completed randomization for its Phase 1b INFLO-1 study of nintedanib DPI.
What Firelda Watch includes for MannKind Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow MannKind Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow MannKind free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more